The immune system provides a large variety of immune checkpoint proteins, which involve both costimulatory and inhibitory proteins. Costimulatory proteins can promote cell survival, cell cycle progression and differentiation to effector and memory cells, whereas inhibitory proteins terminate these processes to halt ongoing inflammation. Immune checkpoint proteins play a pivotal role in atherosclerosis by regulating the activation and proliferation of various immune and non-immune cells, such as T-cells, macrophages and platelets. Upon activation within the atherosclerotic lesions or in secondary lymphoid organs, these cells produce large amounts of pro-atherogenic cytokines that contribute to the growth and destabilization of lesions, which can result in rupture of the lesion causing acute coronary syndromes, such as a myocardial infarction. Given the presence and regulatory capacity of immune checkpoint proteins in the circulation and atherosclerotic lesions of cardiovascular patients, modulation of these proteins by, for example, the use of monoclonal antibodies, offers unique opportunities to regulate pro-inflammatory immune responses in atherosclerosis. In this review, we highlight the latest advances on the role of immune checkpoint proteins, such as OX40-OX40L, CTLA-4 and TIM proteins, in atherosclerosis and discuss their therapeutic potential as promising immunotherapies to treat or prevent cardiovascular disease.
Introduction
In atherosclerosis, both innate and adaptive immune cells contribute to plaque development, progression and destabilization. Upon endothelial injury, circulating monocytes infiltrate the arterial wall and differentiate into macrophages that engulf lipids and promote inflammation by secretion of pro-inflammatory mediators (Hansson et al., 2006) . Subsequently, antigen-presenting cells (APCs), such as dendritic cells (DCs) , are recruited to the lesion, further promoting the pro-inflammatory responses by activation and recruitment of T-cells (Witztum and Lichtman, 2014) . Upon activation, effector T-cells produce large amounts of pro-atherogenic cytokines that contribute to both the growth and destabilization of lesions, which eventually can result in rupture of the lesion. This crucial interaction between APCs and T-cells is tightly regulated by a 'three signal model': (1) display of a surface complex consisting of antigen (e.g. oxLDL) bound on a major histocompatibility complex (MHC) protein class I or II (MHC I or II) to a T-cell receptor (TCR) on a T-cell (CD8 + or CD4 + ), (2) costimulation by immune checkpoint proteins and (3) cytokines. Immune checkpoint proteins comprise costimulatory and inhibitory proteins that can either induce or inhibit activation of T-cells. Naive T-cells that only receive signal 1 without costimulatory signal 2 become anergic or die through apoptosis. Moreover, it has been shown that engagement of costimulatory ligand/receptor pairs triggers an accumulation of receptors and protein complexes at the centre of the immunological synapse, which then amplifies and enhances the duration of TCR signalling (Wulfing and Davis, 1998) . The cytokine environment, signal 3, then induces naïve CD4 + T-cells to differentiate into various T-cell subsets, such as T helper (Th)1 cells, Th2 cells, Th17 cells and regulatory T-cells (Tregs), with each a distinct set of cytokines is released upon activation. The majority of the pathogenic CD4 + T-cells in atherosclerosis are Th1 cells, which produce proinflammatory cytokines such as IFN-γ and TNF-α and express the Th1 specific transcription factor T-box expressed in T-cells (T-bet) (Witztum and Lichtman, 2014) . High levels of IFN-γ stimulate the recruitment of macrophages, DCs and T-cells to the plaque, increase lipid uptake by macrophages and activate APCs (Gupta et al., 1997; Whitman et al., 2000) . Correspondingly, LDLr −/− mice deficient in T-bet (Buono et al., 2005) or ApoE −/− mice deficient in IFN-γ (Whitman et al., 2002) show attenuated atherosclerosis. Th2 cells are known to produce IL-4, IL-5 and IL-13 and are recognized by the expression of the transcription factor trans-acting T-cell-specific transcription factor-3 (GATA-3).
The role of Th2 cells in atherosclerosis remains controversial as it is strongly dependent on the mouse model, disease stage and Th2-hallmark cytokine of interest. IL-5 and IL-13 have been shown to be protective in atherosclerosis (Binder et al., 2004; Cardilo-Reis et al., 2012) , whereas IL-4 has been shown to be both anti-and pro-atherogenic (Huber et al., 2001; King et al., 2002; Davenport and Tipping, 2003) . In humans, high numbers of Th2 cells were associated with a decreased mean common carotid intima-media thickness, indicative of a protective role for Th2 immunity in cardiovascular disease (Engelbertsen et al., 2013) . Another well-debated T-cell subset in the cardiovascular field is the Th17 cell, which is driven by the transcription factor RORγt and the cytokines TGF-β and IL-6 and mainly produces IL-17 (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006) . IL-17 induces tissue inflammation and is therefore commonly associated with autoimmune diseases (Park et al., 2005; Steinman, 2007) . However, the role of Th17 cells in atherosclerosis is controversial as previously discussed in a review by Taleb et al., appointing both an anti-and pro-atherogenic role to IL-17 (Taleb et al., 2015) . Tregs play an important role in the regulation of immune responses in atherosclerosis through suppression of immune cell proliferation and cytokine production (Foks et al., 2015) . Tregs are characterized by the expression of the surface molecules CD4 and CD25, and expression of the transcription factor Forkhead box protein P3 (Foxp3) (Hori et al., 2003) and their mechanism-of-action and therapeutic potential were extensively discussed previously (Foks et al., 2015) . Besides CD4 + T-cells, cytotoxic CD8 + T-cells have also been found in atherosclerotic lesions (Gewaltig et al., 2008 (Yin et al., 2016) .
Immune checkpoint proteins
The immune system provides a large variety of stimulatory and inhibitory immune checkpoint proteins (signal 2), and each pathway has its own unique effect on the fate of individual immune cells. Signalling through stimulatory immune checkpoint proteins can promote cell survival, cell cycle progression and differentiation to effector and memory cells, whereas inhibitory immune checkpoint protein signalling can terminate these processes directly or indirectly by the induction of Tregs. Costimulation can be provided in cis, meaning that both signals 1 and 2 are provided by the same APC, or in trans, in which signal 2 is provided by a different or so-called 'bystander' APC than signal 1 (Roska and Lipsky, 1985; Liu and Janeway, 1992; Ding and Shevach, 1994) . Most of the immune checkpoint proteins belong to either the B7 (Leitner et al., 2010) or TNF (Croft, 2009) superfamilies. The B7 superfamily plays an important role in regulating T-cell function, and its members such as CD28, CTLA-4 and PD-1 are promising therapeutic targets. Members of the TNF superfamily, such as CD40 and OX40, also provide costimulation but additionally comprise molecules with cytoplasmic death domains, which are involved in apoptosis. Furthermore, the T-cell immunoglobulin and mucin domain (TIM) family also consists of potent stimulatory and inhibitory checkpoint proteins (Kuchroo et al., 2003) . Not surprisingly, many of the known stimulatory and inhibitory immune checkpoint proteins are expressed on immune and non-immune cells in the circulation and atherosclerotic lesions of cardiovascular patients (de Boer et al., 1997; Kim et al., 2008) and affect atherosclerosis in various ways (Figures 1 and 2 ). In the next section, we will provide an up-to-date overview of the different immune checkpoint proteins involved in cardiovascular disease and discuss whether their modulation represents a promising immunotherapy to treat or prevent atherosclerosis.
Pro-atherogenic immune checkpoint proteins
The CD28-CD80/86 pathway
The first identified and best characterized costimulatory molecules belonging to the B7 superfamily are CD80 (B7.1) and CD86 (B7.2), expressed on APCs, which bind to their receptor CD28, expressed on T-cells, B cells, thymocytes and macrophages (Sharpe and Freeman, 2002) . CD28-CD80/ CD86 signalling is essential for the activation, proliferation, cytokine secretion and survival of T-cells, and in the absence of CD28 costimulation, T-cells become anergic (Lenschow et al., 1996) . Several costimulatory molecules, such as OX40, CTLA-4 (ICOS) and CD27, only exhibit low expression on naive T-cells but are up-regulated following TCR and CD28 signalling. Both CD80 and CD86 and CD28 are expressed on macrophages in human atherosclerotic lesions (de Boer et al., 1997) . Dopheide et al. showed that monocyte-derived DCs from patients with coronary artery disease have elevated expression of CD80 and CD86 compared with DCs from healthy controls (Dopheide et al., 2007) . In experimental atherosclerosis, it was shown that LDLr −/− mice deficient in CD80/CD86 develop smaller atherosclerotic lesions in both Figure 1 Costimulatory pathways of the B7 and TNF(R) families and their involvement in atherosclerosis. Coinhibitory proteins of the B7 and TNF(R) families and their involvement in atherosclerosis. Engel et al., 2009) . Signalling between CD40 and CD40L functions mainly to activate APCs by T-cells (Grewal and Flavell, 1998; Yan et al., 2009) . In humans, CD40L and CD40 are already expressed in early stages of atherosclerosis, and their expression increases with plaque progression (Lutgens and Daemen, 2002) . Besides the membrane-associated form, CD40L also exists in a truncated soluble form, sCD40L (Foy et al., 1996) , and elevated levels of sCD40L have been associated with hypercholesterolaemia, diabetes, ischaemic stroke and acute coronary syndromes and predict increased restenosis after percutaneous coronary and carotid interventions (Garlichs et al., 2001; Cipollone et al., 2003 Cipollone et al., , 2005 Heeschen et al., 2003; Kopp et al., 2003; Sanguigni et al., 2005) . Moreover, Leroyer et al. showed that atherosclerotic plaques obtained from endarterectomies contained CD40L + microparticles that promote intraplaque neovascularization and thereby could influence plaque vulnerability (Leroyer et al., 2008) . As reviewed by Lievens et al., multiple experimental studies showed a proatherogenic role for CD40-CD40L in atherosclerosis (Lievens et al., 2009) , which indicates that blockade of CD40-CD40L might be a valuable therapeutic tool to prevent atherosclerosis development and stabilize existing lesions in cardiovascular patients. However, it must be noted that blocking monoclonal CD40L antibodies have been considered unsafe due to the high incidence of thromboembolic events, probably as a consequence of the formation of unstable platelet aggregates following CD40L inhibition (Boumpas et al., 2003) . Nowadays, attention has shifted towards downstream targets of the CD40-CD40L signalling pathway, such as the TNF-receptor-associated factor (TRAF) family of proteins (Jansen et al., 2016) .
Daemen
The OX40-OX40L pathway OX40L (CD252 or TNFSF4) and OX40 (CD134 or TNFRSF4) are costimulatory members of the TNF and TNF receptor family. OX40 is primarily expressed on CD4 + T-cells and can interact with OX40L expressed by DCs, macrophages, mast cells, vascular endothelial cells and activated B cells (Baum et al., 1994; al-Shamkhani et al., 1996; Malmstrom et al., 2001) . In contrast to other costimulatory molecules, OX40 and OX40L are expressed 2-3 days after activation. The interaction between OX40L and OX40 enhances the proliferation, differentiation and survival of (memory) T-cells and prevents the development of Tregs (Sugamura et al., 2004; So and Croft, 2007) . Furthermore, activated OX40 + T-cells drive isotype switching of B cells via interaction with OX40L and interruption of the OX40-OX40L pathway (Stuber and Strober, 1996) . The costimulatory OX40-OX40L pathway is of interest in cardiovascular disease, since it has been shown that in humans, single nucleotide polymorphisms (SNPs) in both the OX40 and OX40L genes affect the incidence of cardiovascular disease Ria et al., 2006; Olofsson et al., 2009) . Increased levels of OX40 + T-cells have been found in the circulation and atherosclerotic plaques of cardiovascular patients (Yan et al., 2009; Dumitriu et al., 2012) . Moreover, serum levels of a soluble form of OX40L correlated positively with carotid intima-media thickness (Peng et al., 2010) and with serum C-reactive protein levels (Shi et al., 2011) . The importance of the OX40-OX40L pathway is further confirmed in experimental models of atherosclerosis. OX40L is, for example, located in the quantitative trait locus (QTL) Ath1 that renders Bl6 mice more susceptible to atherosclerosis than C3H/He or BALB/c mice (Paigen et al., 1987; Wang et al., 2005) and OX40 is located in another mouse QTL for atherosclerosis, Athsq1 (Welch et al., 2001) , a region that is syntenic with a QTL for myocardial infarction in humans . OX40L-deficient mice develop smaller atherosclerotic lesions than wild-type mice, whereas mice overexpressing OX40L display increased atherosclerotic lesion development . In addition, interruption of the OX40-OX40L interaction using an OX40L-blocking antibody leads to a 53% reduction in initial atherosclerotic lesion development . Another study showed that ApoE −/− OX40L −/− mice have, in addition to a reduction in atherosclerotic lesion formation, a reduced vascular endothelial growth factor-induced angiogenesis compared with ApoE −/− mice (Nakano et al., 2010) . More recently, it was shown that blockade of OX40L can even induce regression of atherosclerosis in LDLr −/− mice through the up-regulation of IL-5-producing T-cells and oxLDL-specific IgM and reductions in Th2 and mast cells, which indicates that interruption of the OX40-OX40L interaction in combination with lipid lowering may be a novel therapeutic strategy to treat cardiovascular patients with well-established lesions (Foks et al., 2013a) .
The CD137-CD137L pathway CD137 (4-1BB, TNFRSF9) and CD137L (4-1BBL, TNFSF9) are members of the TNF(R) superfamily. CD137 is constitutively expressed on resting monocytes, DCs, neutrophils and Tregs but can also be found on activated CD4 + and CD8 + T-cells, NK cells, NKT cells and mast cells (Kwon et al., 1989; Pollok et al., 1993; Vinay and Kwon, 1998; Heinisch et al., 2000; Nishimoto et al., 2005) . Upon activation, CD137 expression is slowly increased within hours, peaks around 60 h, and remains stably expressed (Pollok et al., 1993) . CD137 binds to its ligand CD137L, which is expressed on monocytes, macrophages, DCs and activated B and T-cells (Goodwin et al., 1993; Pollok et al., 1994) . Interaction of CD137 with CD137L initiates costimulatory responses via downstream signalling through TNF receptor-associated factor-2 and activation of NF-κB, which results in enhanced T-cell proliferation and IL-2 production (Jang et al., 1998) . Interestingly, CD137-CD137L signalling affects CD8 + T-cell proliferation more vigorously than CD4 + T-cell proliferation (Shuford et al., 1997) .
Moreover, CD137-CD137 signalling also affects humoral responses since engagement of CD137L induces B cell proliferation and immunoglobulin synthesis (Pauly et al., 2002) . A possible role for the CD137-CD137L pathway in the pathogenesis of cardiovascular disease was first shown by Drenkard et al. who found that CD137 is expressed on human endothelial cells in the arterial wall at sites of inflammation and enhances the migration of monocytes into the intima (Drenkard et al., 2007) . This was confirmed by Olofsson et al. who showed that human atherosclerotic arteries contain 17 times higher levels of CD137 mRNA in comparison with healthy arteries and that CD137 is mainly colocalized with endothelial cells and CD8 + T-cells (Olofsson et al., 2008) . Additionally, CD137 expression, either soluble or membrane-bound, is elevated in patients with acute coronary syndrome (ACS) compared with healthy controls (Dongming et al., 2010 which was attributed to reduced pro-inflammatory cytokines, such as IFN-γ, MCP-1 (CCL-2) and TNF-α, released by endothelial cells and monocytes/macrophages (Jeon et al., 2010) . These studies show an important role for CD137-CD137L signalling in atherosclerosis, and interruption of the pathway using a blocking CD137 antibody might inhibit cardiovascular disease.
The CD30-CD30L pathway CD30 (TNFRSF8) and CD30L (TNFSF8, CD153) also belong to the TNF(R) superfamily and, similar to OX40 and OX40L, are mainly expressed on activated immune cells. Whereas CD30 and CD30L are both present on activated B-and T-cells, and especially CD4 + T-cells of both Th1 and Th2 phenotypes, CD30L is also expressed on other cell types, such as mature DCs, macrophages and mast cells. Triggering via CD30-CD30L has been shown to induce activation and proliferation of T-cells, through TRAF1-and TRAF2-mediated NF-κB activation (Lee et al., 1996; Duckett et al., 1997) . Furthermore, the CD30-CD30L pathway has been implicated as a major player in secondary humoral immune responses (Shanebeck et al., 1995; Gaspal et al., 2005; Kennedy et al., 2006) . Only limited research has been performed to establish the CD30-CD30L pathway in cardiovascular diseases. Macrophages bearing CD30 have been identified in ruptured plaques of patients with coronary artery disease (Boyle, 1997) , and in mice, it was shown that treatment with a blocking anti-CD30L antibody reduced atherosclerosis by 35% in LDLr −/− mice fed a Western-type diet for 8 weeks (Foks et al., 2012) . This reduction in atherosclerosis was associated with reduced adventitial T-cell numbers, reduced percentages of CD4 + T-cells in the spleen and lymph nodes and with strongly reduced splenocyte proliferation. This identifies anti-CD30L treatment as a novel therapeutic modality in the inhibition of atherosclerotic lesion development and the prevention of acute cardiovascular syndromes.
Anti-atherogenic immune checkpoint proteins
The CTLA-4-CD80/CD86 pathway Similar to CD28, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152), a member of the B7 family, binds to the costimulatory molecules CD80 and CD86. Whereas the interaction between CD80/CD86 and CD28 promotes T-cell responses, CTLA-4 binding to CD80/CD86 inhibits T-cell activation and proliferation (Walunas et al., 1994; Krummel and Allison, 1995) . CTLA-4 is a type 1 transmembrane glycoprotein of the immunoglobulin superfamily (Brunet et al., 1987) and is mainly expressed on Tregs and on activated CD4 + and CD8 + T-cells (Krummel and Allison, 1995; Perkins et al., 1996; Takahashi et al., 2000) but can also be found on a variety of other cells such as monocytes (Wang et al., 2002) and activated B cells (Pioli et al., 2000) . There is limited information on CTLA-4 in cardiovascular patients. One study describes reduced circulating Treg numbers and function in both patients with non-ST elevation acute coronary syndrome and in stabilized patients (6-12 months after ACS) in comparison with healthy subjects (Hasib et al., 2016) . (Matsumoto et al., 2016) .
CTLA-4 overexpression reduced the number of lesional CD4 + T-cells and effector T-cells in lymphoid organs by impairment of their proliferative capacity and a reduction in cytokine secretion such as IFN-γ. Moreover, maturation of DCs, for example, CD80 and CD86 expression, was decreased in CTLA-4 overexpressing mice, which also contributes to decreased T-cell activation in these mice. In line with these findings, treatment with a mimetic of CTLA-4, CTLA-4 IgG (abatacept), ameliorates homocysteine-accelerated atherosclerosis in ApoE −/− mice (Ma et al., 2013) and prevents intimal thickening by 59% in hypercholesterolaemic ApoE3*Leiden mice in a mouse model for post-interventional remodelling (Ewing et al., 2013) . Furthermore, treatment with abatacept results in a 78% reduction in accelerated atherosclerosis development, whereas treatment with a CTLA-4 blocking antibody strongly increased lesion size by 67% (Ewing et al., 2013) . The atheroprotective effect of abatacept was attributed to a reduction in the activation of Th1 and Tregs, with concomitant reduced serum levels of IFN-γ and elevated IL-10. In conclusion, promoting CTLA-4 activity might be a useful strategy to prevent atherosclerosis.
The PD-1-PD-L1/2 pathway
Another coinhibitory molecular pair of the B7-CD28 family is formed by programmed cell death 1 (PD-1, CD279) (Ishida et al., 1992) , which binds to programmed deathligand 1 (PD-L1, B7-H1, CD274) (Dong et al., 1999; Freeman et al., 2000) and 2 (PD-L2, B7-DC, CD273) (Latchman et al., 2001; Tseng et al., 2001) . PD-1 is mainly expressed on activated T-cells but is also expressed on B cells and activated monocytes (Agata et al., 1996; Greenwald et al., 2005) . PD-L1 is constitutively expressed on T-cells, APCs and bone marrow-derived mast cells and can also be found on non-haematopoietic cell types, such as vascular endothelial cells, epithelial cells and muscle cells (Liang et al., 2003; Greenwald et al., 2005) . In contrast, expression of PD-L2 is highly restricted to DCs and activated macrophages (Latchman et al., 2001; Keir et al., 2007) . The interaction between PD-1 and PD-L1/2 inhibits T-cell proliferation and cytokine secretion. Patients suffering from coronary artery disease show significantly decreased expression of PD-1 and PD-L1 on T-cells and myeloid DCs, which subsequently enhance CD4 + and CD8 + T-cell proliferation and production of proinflammatory cytokines (Lee et al., 2009) . Previously, it has been shown that PD-1 is up-regulated on aortic T-cells in hypercholesterolaemic LDLr −/− mice (Bu et al., 2011) , whereas PD-L1 and PD-L2 are present on macrophages and DCs in aortic lesions (Gotsman et al., 2007) . A combined deficiency of PD-L1 and PD-L2 in LDLr −/− mice aggravates atherosclerosis and increases the number of lesional CD4 + and CD8 + T-cells (Gotsman et al., 2007) .
Furthermore, LDLr −/− mice deficient in PD-1 or treated with blocking anti-PD-1 also showed increased atherosclerosis development (Bu et al., 2011; Cochain et al., 2014) . Similar to PD-L1 and PD-L2 deficiency, lesions of LDLr
mice contained high numbers of T-cells and macrophages, and TNF-α levels in serum were increased. Future research should elucidate whether stimulation of the PD-1/PD-L1/2 pathway could be a successful therapeutic approach to inhibit atherosclerosis.
The ICOS-ICOSL pathway
Inducible costimulatory molecule (ICOS; also known as CTLA-4) and its ligand ICOSL (B7h) are also members of the B7-CD28 family. ICOS is essential for the maintenance of follicular T helper (Tfh) cells and is rapidly induced on activated T-cells and resting memory T-cells (Weber et al., 2015) . ICOSL is expressed on B cells, a small subset of T-cells, monocytes, macrophages, DCs and in non-lymphoid tissues, such as the lung (Swallow et al., 1999; Yoshinaga et al., 1999; Ling et al., 2000) . ICOS −/− mice show impaired humoral immune responses and germinal centre reactions (McAdam et al., 2001; Tafuri et al., 2001) , and both ICOS-and ICOSL-deficient T-cells show impaired proliferative capacity and IL-2 production (Tafuri et al., 2001; Nurieva, 2005) . Stimulation of ICOS-ICOSL signalling in CD4 T-cells cultured with anti-CD3 increases the production of IL-4 but also of IFN-γ, the hallmark cytokine of Th1 responses (McAdam et al., 2000) . In patients suffering from myocardial infarction or stable angina, decreased numbers of Tregs and ICOS + -Treg subsets have been found (Ghourbani Gazar et al., 2012) . In experimental atherosclerosis models, the ICOS-ICOSL pathway has also been linked with Tregs as reduced Tregs numbers with reduced suppressive capacity were responsible for a significant 43% increase in atherosclerotic lesion development in the aortic root of chimeric LDLr −/− ICOS −/− mice (Gotsman et al., 2006 
The GITR-GITRL pathway
Glucocorticoid-induced TNF receptor family related protein (GITR, TNFRSF18) and its ligand GITRL (TNFSF18; also known as TL6) are also members of the TNF(R) superfamily. GITR is constitutively high expressed on Tregs but can also be found in low levels on a range of cell types such as CD4 and CD8 T-cells, NK cells, B cells, macrophages, DCs, endothelial cells and smooth muscle cells (Shimizu et al., 2002; Ronchetti et al., 2004) . The role of GITR on Tregs remains to be fully elucidated as some studies show that GITR signalling in Tregs attenuates their suppressive capacity (McHugh et al., 2002; Shimizu et al., 2002) , whereas GITR −/− Tregs do not show functional impairments (Ronchetti et al., 2002) . Upon activation of naïve T-cells, GITR expression peaks after 24 h and induces T-cell proliferation and cytokine production (Tone et al., 2003; Kanamaru et al., 2004) . GITRL is mainly expressed on APCs and endothelial cells (Gurney et al., 1999; Kim et al., 2003; Tone et al., 2003) and after activation with proinflammatory stimuli induces the production of IL-1β, IL-8, TNF-α, MCP-1, iNOS and MMP9 (Shin et al., 2002; Bae et al., 2008) . GITR and GITRL are mainly expressed in macrophage rich areas of human atherosclerotic lesions and upon GITR/GITRL signalling, human and mouse monocytes/macrophages produce MMP9 and TNF-α (Kim et al., 2006; Bae et al., 2008) . Furthermore, GITR positive cells overlap with Foxp3 + T-cells found in human atherosclerotic lesions, and their frequency was significantly lower in atherosclerotic lesions compared with healthy arterial walls (de Boer et al., 2007) . Recently, it was shown that LDLr −/− mice constituted with bone marrow from B cell-specific GITRL transgenic mice show significantly smaller lesions than control mice (Meiler et al., 2016) . This decrease in atherosclerosis was associated with increased Tregs and also an increase in effector memory CD4 + T-cells as a consequence of enhanced proliferation. Although more research is needed to fully understand the GITR-GITRL pathway in atherosclerosis, current studies indicate a protective role for GITR-GITRL, suggesting that stimulation of this pathway might benefit cardiovascular patients.
The CD27-CD70 pathway
Another costimulatory pair of the TNF(R) family involved in T-cell activation is formed by CD27 and CD70 (TNFSF7). CD27 is a transmembrane homodimer constitutively expressed on naive CD4 + and CD8 + T-cells, early thymocytes, B cells and NK cells (Jacquot, 2000; Nolte et al., 2009) . CD70 is a type II transmembrane glycoprotein expressed on activated DCs, macrophages, B cells and activated T-cells (Bowman et al., 1994; de Boer et al., 1997; Tesselaar et al., 2003) . Interaction of CD27 with CD70 activates the NF-κB and JNK pathways (Ramakrishnan et al., 2004) and enhances the proliferation and survival of effector and memory T-cells (Hendriks et al., 2003) . Moreover, CD27 and CD70 are essential for Treg development (Coquet et al., 2013) . In humans, CD4 + CD25 + T-cells expressing CD27 represent a highly suppressive Treg subset (Hoffmann et al., 2004; Godfrey et al., 2005) . Sardella et al. reported that patients with myocardial infarction have decreased CD27 + Tregs compared with healthy individuals (Sardella et al., 2007) . Both CD27 and CD70 are expressed on T-cells and macrophages in human atherosclerotic lesions (de Boer et al., 1997), and it has been shown that CD70 expression is higher in ruptured carotid atherosclerotic lesions than in stable lesions (Winkels et al., 2017) . Using transgenic overexpression of CD70 on B cells in ApoE*3-Leiden mice, Olffen et al. constitutively triggered CD27 signalling on T-cells, which resulted in enhanced numbers of IFN-γ producing effector T-cells and inflammatory Ly6C hi monocytes (van Olffen et al., 2010) .
Surprisingly, these mice were protected against atherosclerosis, which was ascribed to increased susceptibility of the Ly6C hi monocytes to undergo apoptosis and extremely reduced oxLDL-specific antibodies as a consequence of B cell loss following chronic CD27-CD70 stimulation. Recently, more insight was gained on the exact contribution of CD70 in atherosclerosis. Two models of atherosclerosis, 18-weekold chow-fed ApoE −/− CD70 −/− mice and CD70-deficient bone marrow chimeras fed a high-fat diet, show more advanced atherosclerotic lesions compared with their controls (Winkels et al., 2017) . This pro-atherogenic effect of CD70 deficiency was predominantly linked to an impaired macrophage viability and function. CD70-deficient macrophages showed an inactive metabolic profile, increased susceptibility to apoptosis and were inefficient in the uptake and efflux of cholesterol, contributing to the progression of atherosclerosis Altogether, these data suggest a coinhibitory role for the CD27-CD70 pathway in atherosclerosis, and modulation with agonistic antibodies might have therapeutic potential for the prevention of cardiovascular diseases.
TIM proteins
A family of type 1 transmembrane proteins, the T-cell immunoglobulin and mucin domain (TIM) proteins, are expressed on various immune cells and play an important role in the regulation of innate and adaptive immune responses by providing costimulatory or coinhibitory signals. Moreover, TIM proteins can recognize the 'eat me' signals on the cell surface of apoptotic cells and are involved in the engulfment of these apoptotic cells (Freeman et al., 2010) . This is of particular interest for atherosclerosis since the clearance of apoptotic cells, a process called efferocytosis, limits lesion growth by releasing the anti-inflammatory cytokines IL-10 and TGF-β (Tabas, 2010) . Three TIM genes have been identified in humans (TIM-1, −3 and −4) and are associated with enhanced susceptibility to allergy and several autoimmune diseases, such as experimental autoimmune encephalomyelitis and diabetes (Kuchroo et al., 2003; Freeman et al., 2010) . TIM-1 is expressed on activated T-cells, in particular Th2 cells, DCs and regulatory B cells (de Souza et al., 2005; Xiao et al., 2012) . Mice deficient in TIM-1 have increased susceptibility to autoimmunity as shown by increased Th2 responses (Curtiss et al., 2012) and decreased IL-10 producing Bregs (Yeung et al., 2015) . There is virtually no information available on TIM-1 in cardiovascular patients. An association between TIM-1 and lesion occurrence in carotid arteries in a human population-based study has been found using proteomic arrays (Lind et al., 2015) . Recently, it was shown that blockade of TIM-1 with a monoclonal antibody aggravates atherosclerosis development by 45% in LDLr −/− mice compared to treatment with an isotype control (Foks et al., 2016) . Mechanistically, atherosclerotic lesions of mice treated with anti-TIM-1 showed increased number of CD4 + T-cells. Th2 responses were strongly enhanced, whereas circulating anti-atherogenic Tregs were significantly decreased by 76%.
TIM-3 was first discovered as a specific marker for Th1 cells (Monney et al., 2002) but is also expressed on a variety of immune cells such as NK cells, monocytes, macrophages and mast cells (Nakae et al., 2007) . TIM-3 terminates IFN-γ driven inflammation by inducing cell death of T-cells after binding to its ligand galectin-9 (Zhu et al., 2005) . In addition, TIM-3 can induce Treg activity (Sehrawat et al., 2009) . Hou et al. showed that patients with atherosclerosis have augmented TIM-3 expression on NK cells, which might affect NK cell function during atherosclerosis (Hou et al., 2012) . Furthermore, patients suffering from atherosclerosis have increased circulating regulatory PD-1 + TIM-3 + CD8 + T-cells compared with healthy controls (Qiu et al., 2015) . These regulatory CD8 + T-cells are highly proliferative and produce increased IL-10 and decreased IFN-γ and TNF-α compared with CD8 T-cells that do not (co) express PD-1 and TIM-3. A study in hypercholesterolaemic LDLr −/− mice showed that blockade of TIM-3 augmented early and advanced atherosclerosis and enhanced immune responses by increasing circulating monocytes and plaque macrophages, and by decreasing IL-10 producing Tregs and Bregs (Foks et al., 2013b) . TIM-4 expression is restricted to macrophages, DCs and B1 cells (Kobayashi et al., 2007; Albacker et al., 2010) . Mice deficient in TIM-4 showed hyperactive T and B cell responses, and their peritoneal macrophages were unable to clear apoptotic bodies in vivo (Rodriguez-Manzanet et al., 2010) . Interestingly, an SNP in the TIM-4 encoding gene is associated with lowered levels of LDL and triglycerides (Kathiresan et al., 2009; Albacker et al., 2013) . However, it is not known if this SNP affects the function of TIM-4. Another study shows that TIM-4 mRNA negatively correlates with LDL levels in mice with type 2 diabetes (Zhao et al., 2016) . In mice, blockade of TIM-4 using a blocking monoclonal antibody (clone 21H12) significantly enhanced atherosclerosis development by 45% (Foks et al., 2016) . Anti-TIM-4-treated mice show elevated circulating CD4 + CD69 + T-cells and aortic CD4 + T-cell numbers. Particularly, IFN-γ-producing Th1 cells were increased. Moreover, the efferocytosis capacity of macrophages in the atherosclerotic lesion of anti-TIM-4-treated mice was impaired, contributing to the observed enlarged lesions. In the future, approaches to promote TIM proteins may represent novel therapeutic strategies to inhibit atherosclerotic lesion development and prevent cardiovascular diseases.
Clinical implications
In cardiovascular disease, the modulation of immune checkpoint proteins can be a powerful tool to target specific stages of atherosclerosis or specific cell types involved in the pathogenesis of atherosclerosis (Figure 3) . A highly relevant feature of costimulatory and inhibitory pathways is that they individually have their unique effect on the behaviour of specific immune cells and thus on the outcome of disease. For example, interference in OX40-OX40L and CD30-CD30L signalling both reduce atherosclerosis via different pathways; anti-OX40L specifically targets Th2 responses and mast cell activity, whereas anti-CD30L limits all CD4 + T-cell responses without affecting a specific T-cell subset or other immune cells. In addition, several costimulatory and inhibitory molecules are involved in the induction and function of Tregs. This enables the development of a treatment that particularly targets different subsets of T-cells. Ultimately, it would be ideal to modulate antigen-specific pro-atherogenic T-cells with blocking costimulatory antibodies and agonistic inhibitory antibodies without affecting all T-cells and other immune cells to limit any adverse effects on the immune system. Although several candidates of atherosclerosis-specific antigens have been investigated, such as oxLDL, HSP60 and ApoB100, to date, an exclusively atherosclerosis-associated antigen has not yet been identified, which makes it difficult to specifically target the pro-atherogenic T-cells. However, some costimulatory molecules, such as OX40, are virtually absent on naïve T-cells but are up-regulated on activated T-cells. Targeting these costimulatory molecules with blocking antibodies could specifically eliminate the pathogenic T-cells without causing any side effects. Blocking and agonistic antibodies for immune checkpoint proteins have already been extensively explored in cancer and allograft rejections. For example, blocking Figure 3 Modulation of immune checkpoint proteins as a potential immunotherapy to inhibit atherosclerosis. By blockade of costimulatory proteins, such as OX40L and CD30L, or stimulation of coinhibitory proteins, such as CTLA-4 or TIM-4, pro-atherogenic immune responses, such as Th1 and mast cell activation, are inhibited. Anti-inflammatory processes, such as the induction of Tregs and production of oxLDL-lgMs are induced. Possible therapeutic options include the usage of monoclonal anibodies, but future research is necessary before they can be applied in clinical research.
antibodies for CTLA-4 and PD-1 are approved for treatment of patients with several types of cancer (Topalian et al., 2011) . However, recently, multiple case reports show adverse T-celldriven cardiotoxic events (Heinzerling et al., 2016; Johnson et al., 2016) , such as heart failure and myocarditis, of such treatments, and indeed, in contrast to cancer where T-cell activity is highly appreciated, the unwanted activation of the immune system needs to be suppressed in cardiovascular diseases. CTLA-4-Ig has already been established as an effective treatment for human autoimmune diseases including rheumatoid arthritis (Kremer et al., 2003) and psoriasis (Abrams et al., 1999) . However, before such clinical trials can be started for cardiovascular diseases, further characterization of these potential new drug targets is necessary.
Interestingly, some anti-tumour therapy studies have indicated that treatment with a single costimulatory agonist, in addition to existing cytostatic therapy or cancer-antigen vaccination, is not effective or induces adverse immunological events. The co-administration of a second agonist or another factor that stimulates T-cell function is necessary to achieve a greater anti-tumour reactivity. For example, a clinical trial with an anti-CTLA-4 antibody (MDX-010; also known as ipilimumab) in conjunction with anti-cancer antigen vaccination resulted in regression of cancer but unfortunately also induced severe autoimmune diseases in melanoma patients (Phan et al., 2003) . Kocak et al. (2006) showed that a combination therapy in mice with pre-existing tumours with anti-CTLA-4 and anti-4-1BB enhances anti-tumour immunity without any adverse effects on the immune system. Currently, a phase I clinical trial is carried out in which anti-CTLA-4 (ipilimumab) is combined with anti-PD-1 (BMS-936558) to treat melanoma patients (Clinicaltrials.gov, 2009 ).
It may be very likely that a combinatorial therapy may also be very effective in atherosclerosis. More research should be performed to identify the most relevant combinations of blocking and agonistic antibodies for costimulatory and inhibitory checkpoint proteins respectively, which could be used as an immunotherapy to inhibit atherosclerosis.
Conclusion
The expression and function of stimulatory and inhibitory immune checkpoint proteins are significantly affected in cardiovascular patients compared with healthy individuals, promoting a pro-inflammatory environment. Modulation of immune checkpoint proteins by for example monoclonal antibodies, in addition to lipid-lowering treatments, can therefore provide a powerful tool to target specific stages of atherosclerosis or specific cell types involved in the pathogenesis of atherosclerosis. However, immune-related adverse effects present a great challenge for such an immunotherapy, and further characterization of these potential new drug targets is necessary before they can be applied in clinical research.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015 /16 (Alexander et al., 2015a .
